Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

VYNE Therapeutics (VYNE) Shares Outstanding (2016 - 2025)

VYNE Therapeutics filings provide 10 years of Shares Outstanding readings, the most recent being $33.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 124.7% to $33.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.3 million, a 124.7% increase, with the full-year FY2025 number at $33.3 million, up 124.7% from a year prior.
  • Shares Outstanding hit $33.3 million in Q4 2025 for VYNE Therapeutics, up from $19.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $53.5 million in Q3 2021 to a low of $3.0 million in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $14.3 million (2024), compared with a mean of $17.0 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 93.97% in 2022 and later soared 346.37% in 2024.
  • VYNE Therapeutics' Shares Outstanding stood at $3.0 million in 2021, then grew by 8.51% to $3.2 million in 2022, then surged by 336.54% to $14.1 million in 2023, then increased by 5.19% to $14.8 million in 2024, then skyrocketed by 124.7% to $33.3 million in 2025.
  • The last three reported values for Shares Outstanding were $33.3 million (Q4 2025), $19.8 million (Q2 2025), and $16.0 million (Q1 2025) per Business Quant data.